The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1463-1469

  Bouez, Charbel ^a,b   Reynaud, Caroline ^b   Noblesse, Emmanuelle ^a   Thépot, Amélie ^a   Gleyzal, Claudine ^b   Kanitakis, Jean ^a   Perrier, Eric ^c   Damour, Odile ^a,b   Sommer, Pascal ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LYSINE 6 OXIDASE;

ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; DERMIS; ENZYME ACTIVITY; EPIDERMIS; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; KERATINOCYTE; PHENOTYPE; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TRANSMISSION ELECTRON MICROSCOPY;

AMINOPROPIONITRILE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; COLLAGEN; DERMIS; FIBROBLASTS; HUMANS; INTERMEDIATE FILAMENT PROTEINS; KERATIN-10; KERATINOCYTES; KERATINS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN-LYSINE 6-OXIDASE; SKIN NEOPLASMS;

EID: 33645070536     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1456     Document Type: Article

References (55)

1. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72.
2. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998;16:387-98.
3. Molnar J, Fong KS, He QP, et al. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 2003;1647:220-4.
4. Rodriguez C, Raposo B, Martinez-Gonzalez J, Casani L, Badimon L. Low density lipoproteins down-regulate lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler Thromb Vasc Biol 2002;22:1409-14.
5. Maki JM, Rasanen J, Tikkanen H, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002;106:2503-9.
6. Sibon I, Sommer P, Lamaziere JM, Bonnet J. Lysyl oxidase deficiency: a new cause of human arterial dissection. Heart 2005;91:e33.
7. Gilad GM, Kagan HM, Gilad VH. Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. Neurosci Lett 2005;376:210-4.
8. Kuivaniemi H, Peltonen L, Kivirikko KI. Type IX Ehlers-Danlos syndrome and Menkes syndrome: the decrease in lysyl oxidase activity is associated with a corresponding deficiency in the enzyme protein. Am J Hum Genet 1985;37:798-808.
9. Khakoo A, Thomas R, Trompeter R, Duffy P, Price R, Pope FM. Congenital cutis laxa and lysyl oxidase deficiency. Clin Genet 1997;51:109-14.
10. Pinnell SR. Molecular defects in the Ehlers-Danlos syndrome. J Invest Dermatol 1982;79 Suppl 1:90-2s.
11. Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol 1997;150:497-507.
12. Peyrol S, Galateau-Salle F, Raccurt M, Gleyzal C, Sommer P. Selective expression of lysyl oxidase (LOX) in the stromal reactions of broncho-pulmonary carcinomas. Histol Histopathol 2000;15:1127-35.
13. Noblesse E, Cenizo V, Bouez C, et al. Lysyl oxidase-like and lysyl oxidase are present in the dermis and epidermis of a skin equivalent and in human skin and are associated to elastic fibers. J Invest Dermatol 2004;122:621-30.
14. Wakasaki H, Ooshima A. Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Lab Invest 1990;63:377-84.
15. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 1998;58:1285-90.
16. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002;62:6645-50.
17. Kaneda A, Wakazono K, Tsukamoto T, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004;64:6410-5.
18. He J, Tang HJ, Wang YY, et al. [Expression of lysyl oxidase gene in upper digestive tract carcinomas and its clinical significance]. Ai Zheng 2002;21:671-4.
19. Rost T, Pyritz V, Rathcke IO, Gorogh T, Dunne AA, Werner JA. Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas. Anticancer Res 2003;23:1565-73.
20. Woznick AR, Braddock AL, Dulai M, et al. Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg 2005;189:297-301.
21. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002;62:4478-83.
22. Tsuchiya MI, Okuda H, Takaki Y, et al. Renal cell carcinoma-and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Oncol Rep 2005;13:1033-41.
23. Holtmeier C, Gorogh T, Beier U, et al. Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas. Anticancer Res 2003;23:2585-91.
24. Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res 2003;63:1657-66.
25. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 2005;24:3446-58.
26. Nagaraja GM, Othman M, Fox BP, et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2005; Epub ahead of print.
27. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM. Lysyl oxidase and rrg messenger RNA. Science 1991;253:802.
28. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990;249:796-8.
29. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci U S A 1997;94:12817-22.
30. Giampuzzi M, Botti G, Cilli M, et al. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 2001;276:29226-32.
31. Giampuzzi M, Oleggini R, Di Donato A. Altered adhesion features and signal transduction in NRK-49F cells transformed by down-regulation of lysyl oxidase. Biochim Biophys Acta 2003;1647:239-44.
32. Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 2003;23:2251-63.
33. Palamakumbura AH, Jeay S, Guo Y, et al. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 2004;279:40593-600.
34. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988;106:761-71.
35. Duplan-Perrat F, Damour O, Montrocher C, et al. Keratinocytes influence the maturation and organization of the elastin network in a skin equivalent. J Invest Dermatol 2000;114:365-70.
36. Sommer P, Gleyzal C, Raccurt M, et al. Transient expression of lysyl oxidase by liver myofibroblasts in murine schistosomiasis. Lab Invest 1993;69:460-70.
37. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol 2001;70:1-32.
38. Hajnal A, Klemenz R, Schafer R. Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 1993;53:4670-5.
39. Oberhuber H, Seliger B, Schafer R. Partial restoration of pre-transformation levels of lysyl oxidase and transin mRNAs in phenotypic ras revenants. Mol Carcinog 1995;12:198-204.
40. Kuivaniemi H, Korhonen RM, Vaheri A, Kivirikko KI. Deficient production of lysyl oxidase in cultures of malignantly transformed human cells. FEBS Lett 1986;195:261-4.
41. Csiszar K, Fong SF, Ujfalusi A, et al. Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors. Int J Cancer 2002;97:636-42.
42. Hamalainen ER, Kemppainen R, Kuivaniemi H, et al. Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 1995;270:21590-3.
43. Tan RS, Taniguchi T, Harada H. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Cancer Res 1996;56:2417-21.
44. Hamalainen ER, Jones TA, Sheer D, Taskinen K, Pihlajaniemi T, Kivirikko KI. Molecular cloning of human lysyl oxidase and assignment of the gene to chromosome 5q23.3-31.2. Genomics 1991;11:508-16.
45. Tamura G, Ogasawara S, Nishizuka S, et al. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 1996;56:612-5.
46. Wieland I, Bohm M, Arden KC, et al. Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene 1996;12:97-102.
47. Nellaiappan K, Risitano A, Liu G, Nicklas G, Kagan HM. Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth-muscle cells. J Cell Biochem 2000;79:576-82.
48. Haynes SL, Shuttleworth CA, Kielty CM. Keratinocytes express fibrillin and assemble microfibrils: implications for dermal matrix organization. Br J Dermatol 1997;137:17-23.
49. Li W, Nugent MA, Zhao Y, et al. Lysyl oxidase oxidizes basic fibroblast growth factor and inactivates its mitogenic potential. J Cell Biochem 2003;88:152-64.
50. Giampuzzi M, Oleggini R, Di Donato A. Demonstration of in vitro interaction between tumor suppressor lysyl oxidase and histones H1 and H2: definition of the regions involved. Biochim Biophys Acta 2003;1647:245-51.
51. Costea DE, Johannessen AC, Vintermyr OK. Fibroblast control on epithelial differentiation is gradually lost during in vitro tumor progression. Differentiation 2005;73:134-41.
52. Atula S, Grenman R, Syrjanen S. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp Cell Res 1997;235:180-7.
53. Lagace R, Grimaud JA, Schurch W, Seemayer TA. Myofibroblastic stromal reaction in carcinoma of the breast: variations of collagenous matrix and structural glycoproteins. Virchows Arch A Pathol Anat Histopathol 1985;408:49-59.
54. Decitre M, Gleyzal C, Raccurt M, et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab Invest 1998;78:143-51.
55. Paweletz N, Boxberger HJ. Defined tumor cell-host interactions are necessary for malignant growth. Crit Rev Oncog 1994;5:69-105.